Clinical Trials Browser

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Phase 1 Active not recruiting

98 enrolled

BreastDermatologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

NCT05210413 2026-01-15

SPARTO

Phase 1/2 Active not recruiting

80 enrolled

Other solid neoplasm

Refractory or Recurrent Solid Tumor

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Phase 2 Active not recruiting

33 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05631899 2025-11-24

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Phase 1 Active not recruiting

9 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04058756 2025-10-07

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Phase 1 Active not recruiting

120 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Phase 2 Active not recruiting

19 enrolled

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT06547957 2025-08-13

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

55 enrolled

Tumor-Agnostic

Neoplasms

NCT05751928 2025-07-08

NEO-MIMAJOR

Phase 3 Active not recruiting

411 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT05607953 2025-07-04

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Phase 1 Active not recruiting

60 enrolled

Gastrointestinal

Locally Advanced Pancreatic Adenocarcinoma

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

184 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05662397 2025-02-04

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Phase 1/2 Active not recruiting

77 enrolled

Neoplasms, Recurrence

NCT05522582 2024-10-26

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Phase 2 Active not recruiting

50 enrolled

Other solid neoplasm

Solid Tumors

NCT04833387 2023-01-11

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Phase 2 Active not recruiting

30 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

SPARTO

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

NEO-MIMAJOR

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

ACROPOLI

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer